Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Interpace, Genecast ink partnership deal
November 2019
SHARING OPTIONS:

PARSIPPANY, N.J.—A partnership agreement is under way between Interpace BioPharma Inc., a subsidiary of Interpace Diagnostics Group Inc., and Genecast (Beijing) Biotechnology Co. Ltd. of the Peoples Republic of China (PRC). The agreement covers the joint development, promotion and offering of translational studies and clinical trial solutions to biotech and pharmaceutical companies, with Interpace BioPharma to offer such services worldwide except in the PRC, while Genecast will offer services in the PRC.
 
Du Bo, co-founder and CEO of Genecast, said, “As China plays a more important role in innovative drug development, global multi-center trials with programs in China have become a critical strategy of drug developers. This partnership with Interpace will strengthen our capabilities to provide our customers with high-quality, streamlined one-stop testing services globally and is in line with our strategy of helping pharmaceutical and biotech companies to accelerate their biomarker-driven drug development and drive precision medicine forward.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.